Arca
Skip to content
Tools
Tools

CXCR1, CXCR2: Interleukin-8 receptors, CXCR1/CXCR2

Family in Homo sapiens that 1 drug acts on.

  • Drugs that act on it: 1
  • Approved: 0
  • In phases 1 to 3: 1
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on CXCR1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 1

Approved0

    Phase 30

      Phase 21

      • SX-682

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        SX-682Phase 2Syntrix Biosystems, Inc.Small moleculeInhibitorInterleukin-8 receptors, CXCR1/CXCR2 inhibitor14

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
        A Study of SX-682 in Combination With Proton Craniospinal Irradiation (pCSI) in People With Leptomeningeal DiseaseSX-682Phase 1RecruitingMemorial Sloan Kettering Cancer CenterSep 11, 2026
        Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate CancerSX-682Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)Jun 25, 2026
        SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung CancerSX-682Phase 2RecruitingUniversity of WashingtonJan 7, 2026
        COMPASS Study for Metastatic Castration-resistant Prostate CancerSX-682—RecruitingDuke UniversityJul 3, 2025
        Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate CancerSX-682Phase 1 / Phase 2RecruitingInstitute of Cancer Research, United KingdomJun 3, 2025
        SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaSX-682Phase 1RecruitingRoswell Park Cancer InstituteOct 1, 2024
        Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate CancerSX-682Phase 2RecruitingSyntrix Biosystems, Inc.Jan 29, 2024
        Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)SX-682Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)Nov 29, 2023

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2096909, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.